KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretDoğrulanmış sonuçlanma verisiOrta düzey kalibreGüncel ima edilen olasılık
Before Oct 1, 2027 71%-15.0pt5 seçenek arasında lider
Piyasa kalitesi
33 / 100
Düşük kalite24s Hacim
₺8,9 B
Likidite
₺10,1 B
Düşük likiditeSpread
8.0 pt
Geniş spreadPiyasa verileri
13 dakika önce guncellendi
19 Ağu 26 22:001 Eki 27 3:59
Trendler
0%
0%
0%
0%
Kurallar
If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing the named outcome, then the market resolves to Yes.
Settles via:Food and Drug Administration
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals:
Sık sorulan sorular
- Will the FDA approve intismeran autogene (V940/mRNA-4157)? için güncel oranlar nedir?
- Kalshi, 24 Ağustos 2026 itibarıyla Before Oct 1, 2027 için 71% fiyatlıyor.
- Will the FDA approve intismeran autogene (V940/mRNA-4157)? ne zaman sonuçlanacak?
- Will the FDA approve intismeran autogene (V940/mRNA-4157)? için öngörülen sonuçlanma tarihi 1 Ekim 2027.
- Will the FDA approve intismeran autogene (V940/mRNA-4157)? nasıl sonuçlandırılıyor?
- Kalshi bu piyasayı şu şekilde sonuçlandırır: If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing the named outcome, then the market resolves to Yes.
